26167-45-3Relevant articles and documents
COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS
-
Paragraph 0548, (2014/03/25)
Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
Baker's yeast-mediated synthesis of (R)- and (S)-heteroaryl-ethane-1,2-diols
Podea, Paula Veronica,Paizs, Csaba,Tosa, Monica Ioana,Irimie, Florin Dan
, p. 1959 - 1964 (2008/12/22)
Baker's yeast-mediated enantioselective bioreduction of 1-(heteroaryl)-2-hydroxyethanones and 2-acetoxy-1-(hetero-aryl)ethanones was used for the enantioselective synthesis of both (R)- and (S)-benzofuranyl-, benzo[b]thiophenyl- and benzo[d]thiazolyl-ethane-1,2-diols.
Condensed thiazole derivatives, having 5-HT receptor affinity
-
, (2008/06/13)
Compounds of formula I STR1 in which A is S(O) p or O;p is 0, 1 or 2;g is 0, 1, 2, 3, or 4;n is 2 or 3; andR 1, R 2, R 3, R 4 and R 5 are optional substituents have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer''s disease, senile dementia, cerebral ischemia, obsessive-compulsive behavior, panic attacks, social phobias, eating disorders and anorexia, non-insulin dependent diabetes mellitus, hyperglycemia, and stress.